Oppenheimer reaffirmed their buy rating on shares of Vaccinex (NASDAQ:VCNX) in a research report report published on Monday morning, AnalystRatings.com reports. The brokerage currently has a $22.00 price target on the stock. Oppenheimer also issued estimates for Vaccinex’s Q3 2020 earnings at ($0.53) EPS, FY2020 earnings at ($1.76) EPS, Q1 2021 earnings at ($0.36) EPS, Q2 2021 earnings at ($0.31) EPS, Q3 2021 earnings at ($0.37) EPS, Q4 2021 earnings at ($0.41) EPS, FY2021 earnings at ($1.45) EPS, FY2022 earnings at ($0.90) EPS, FY2023 earnings at $2.40 EPS and FY2024 earnings at $6.60 EPS.
Separately, Zacks Investment Research downgraded Vaccinex from a buy rating to a hold rating in a research report on Saturday, May 16th.
Shares of NASDAQ VCNX opened at $5.58 on Monday. Vaccinex has a 1-year low of $3.22 and a 1-year high of $12.23. The business has a 50-day moving average of $5.75 and a 200-day moving average of $4.70. The company has a market capitalization of $117.95 million, a price-to-earnings ratio of -3.13 and a beta of 1.64.
In other Vaccinex news, Director Albert Friedberg purchased 1,126,760 shares of Vaccinex stock in a transaction that occurred on Friday, July 10th. The stock was purchased at an average price of $3.55 per share, with a total value of $3,999,998.00. Following the completion of the acquisition, the director now owns 439,555 shares of the company’s stock, valued at approximately $1,560,420.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 68.60% of the company’s stock.
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.